Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 3/20 | 0.58 |
| ▸ | SYK | P43405 | 10/20 | 0.55 |
| ▸ | MAP3K12 | Q12852 | 6/20 | 0.45 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.45 |
| ▸ | IDH2 | P48735 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16391618 | 0.89 | IDH1 (0.74) | IDH1SYKIDH2 | |
| SCHEMBL17812914 | 0.83 | IDH2 (0.47) | IDH1SYKIDH2 | |
| SCHEMBL17812905 | 0.83 | SYK (0.50) | IDH1SYKMAP3K12IDH2 | |
| SCHEMBL17812906 | 0.81 | SYK (0.50) | SYKMAP3K12IDH2 | |
| Cyanide SCHEMBL28066875 | 0.76 | IDH1 (0.68) | IDH1SYKIDH2 | |
| SCHEMBL16391777 | 0.74 | IDH1 (0.76) | IDH1IDH2 | |
| SCHEMBL16393287 | 0.74 | IDH1 (1.00) | IDH1IDH2 | |
| SCHEMBL17812909 | 0.74 | IDH2 (0.50) | IDH1SYKMAP3K12IDH2 | |
| SCHEMBL16391799 | 0.74 | IDH2 (0.59) | IDH1IDH2 | |
| SCHEMBL904195 | 0.74 | SYK (0.52) | SYKMAP3K12IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | IDH2, IDH3B, IDH3A | IDH1 4/4885SYK 4358/4885MAP3K12 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.